Dr. Sant P Chawla, MD
Claim this profileSarcoma Oncology Center
Expert in Soft Tissue Sarcoma
Studies Solid Tumors
42 reported clinical trials
59 drugs studied
About Sant P Chawla, MD
Education:
- Earned a Medical Degree from All India Institute of Medical Sciences, New Delhi, India.
Experience:
- Completed Residency in Internal Medicine at All India Institute of Medical Sciences, New Delhi.
- Underwent Specialty training in Medical Oncology at Auckland Hospital, Auckland, New Zealand.
- Achieved Fellowships in Medical Oncology at Fellow Royal Australasian College of Physicians (F.R.A.C.P.) and in Oncology at the University of Texas MD Anderson Cancer Center.
- Serves as Director of the Sarcoma Oncology Center in Santa Monica, CA, and holds clinical faculty positions at UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital, and Cedars Sinai Comprehensive Cancer Center.
- Recognized for conducting over 100 clinical trials for cancer drugs and groundbreaking research in sarcoma oncology.
Area of expertise
1Soft Tissue Sarcoma
Global LeaderStage IV
Stage III
HCV
2Solid Tumors
Stage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Sant P Chawla, MD is currently running
Chemotherapy + Immunotherapy
for Advanced Sarcoma
This trial uses a combination of chemotherapy and immunotherapy to treat patients with advanced sarcoma. The chemotherapy attacks the cancer directly, while the immunotherapy boosts the body's natural defenses to help fight the cancer.
Recruiting1 award Phase 212 criteria
Bria-OTS Immunotherapy
for Breast Cancer
This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.
Recruiting1 award Phase 1 & 27 criteria
More about Sant P Chawla, MD
Clinical Trial Related3 years of experience running clinical trials · Led 42 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Sant P Chawla, MD has experience with
- Nivolumab
- Doxorubicin
- Trabectedin
- Gemcitabine
- Placebo
- L19TNF
Breakdown of trials Sant P Chawla, MD has run
Soft Tissue Sarcoma
Solid Tumors
Cancer
Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sant P Chawla, MD specialize in?
Sant P Chawla, MD focuses on Soft Tissue Sarcoma and Solid Tumors. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Sant P Chawla, MD currently recruiting for clinical trials?
Yes, Sant P Chawla, MD is currently recruiting for 10 clinical trials in Santa Monica California. If you're interested in participating, you should apply.
Are there any treatments that Sant P Chawla, MD has studied deeply?
Yes, Sant P Chawla, MD has studied treatments such as Nivolumab, Doxorubicin, Trabectedin.
What is the best way to schedule an appointment with Sant P Chawla, MD?
Apply for one of the trials that Sant P Chawla, MD is conducting.
What is the office address of Sant P Chawla, MD?
The office of Sant P Chawla, MD is located at: Sarcoma Oncology Center, Santa Monica, California 90403 United States. This is the address for their practice at the Sarcoma Oncology Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.